On October 15, 2024, the U.S. Food and Drug Administration (FDA) approved the use of a wearable treatment device, Optune Lua, in combination with PD-1/PD-L1 immunotherapies or the chemotherapy docetaxel for people with metastatic non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy.  

Optune Lua is a non-invasive, wearable device that delivers electric fields known as Tumor Treating Fields (TTFields) to the body. TTFields exert a physical force on the electrically charged components of dividing cancer cells, causing cell death without significantly affecting healthy cells. Thus, devices like Optune Lua may be able to be added to more traditional cancer treatments, such as immunotherapy or chemotherapy, to potentially enhance their effectiveness. 

This approval is based on the results of the LUNAR study, which looked at people with metastatic NSCLC who had progressed on or after platinum-based chemotherapy. Participants were given either PD-1/PD-L1 immunotherapy or docetaxel with or without the Optune Lua device as treatment. Participants using the Optune Lua device and receiving traditional cancer treatments experienced a significant increase in overall survival—the first meaningful improvement for this population in several years. 

Please speak with your healthcare team to see if Optune Lua may be an option for you. If you have questions about treatment, trials, or biomarker testing, contact our LungMATCH team at support@go2.org or 1-800-298-2436.